Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma - Trial NCT04157127
Access comprehensive clinical trial information for NCT04157127 through Pure Global AI's free database. This Phase 1 trial is sponsored by Baylor College of Medicine and is currently Recruiting. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 43 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Baylor College of Medicine
Timeline & Enrollment
Phase 1
Aug 03, 2020
Nov 01, 2025
Primary Outcome
MTD of DC Vaccine,Number of participants who experienced Dose Limiting Toxicities (DLTs)
Summary
This is a phase 1, first in man, dose escalation study for safety and feasibility for
 administration of 3 doses of DC vaccine for pancreatic adenocarcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04157127
Non-Device Trial